Inhalation Sciences receives 2.4 MSEK order from global corporation based in Europe
September 19, STOCKHOLM. Inhalation Sciences (ISAB) has received an order for a PreciseInhale system, together with two of its in vitro exposure modules. The order is initially worth apoprox. 2.4 MSEK.
PreciseInhale®, together with its wide range of modules producing controlled aerosol exposures, represents a complete solution for companies studying inhalation and aerosols in pre-clinical experiments. It enables earlier and more extensive preclinical evaluation of candidate substances for inhalation. The present order is for PreciseInhale®, and two in vitro modules: DissolvIt™ and XposeALI™.
ISAB CEO Lena Heffler: "This order is the result of a successful, earlier research collaboration where we were able to deliver important data to the customer's development project. The customer is a large global company at the forefront of the inhalation field. In a sector like ours, which is relatively small, but highly competitive, we sometimes choose not to directly name customers, to better protect their research and strategic investments. But it is always extra exciting to be involved with, and contribute to, new products and product areas. We’re delighted with this result.”
For more information about Inhalation Sciences please contact:
Lena Heffler, CEO
Email: lena.heffler@inhalation.se
Phone: +46 (0)70 205 96 20
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.
The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on September 19, 2018.
Tags: